泰和诚医疗 2026年年度报告和过渡报告

*Not for trading, but only in connection with the listing of the American depositary shares on the New York Stock Exchange under the symbol “CCM.”Securities registered or to be registered pursuant to Section12(g)of the Act: 130,251,685 ordinary shares, including 84,463,737 Class A ordinary shares (excluding treasury shares issued and reserved for future issuance upon the exercising or vesting of awardsgranted under our share incentive plans) and 45,787,948 Class B ordinary shares, outstanding as of December 31, 2025 Table of Contents TABLE OF CONTENTS PagePARTI3ITEM1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS3ITEM2. OFFER STATISTICS AND EXPECTED TIMETABLE3ITEM3. KEY INFORMATION3ITEM4. INFORMATION ON THE COMPANY45ITEM4A. UNRESOLVED STAFF COMMENTS77ITEM5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS77ITEM6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES108ITEM7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS117ITEM8. FINANCIAL INFORMATION119ITEM9. THE OFFER AND LISTING120ITEM10. ADDITIONAL INFORMATION121ITEM11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK136ITEM12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES137PARTII139ITEM13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES139ITEM14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS139ITEM15. CONTROLS AND PROCEDURES139ITEM16A. AUDIT COMMITTEE FINANCIAL EXPERT140ITEM16B. CODE OF ETHICS140ITEM16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES140ITEM16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES140ITEM16E. PURCHASE OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS141ITEM16F. CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT141ITEM16G. CORPORATE GOVERNANCE141ITEM16H. MINE SAFETY DISCLOSURE141ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS141ITEM 16J INSIDER TRADING POLICIES141ITEM 16K CYBERSECURITY141PARTIII143ITEM17. FINANCIAL STATEMENTS143ITEM18. FINANCIAL STATEMENTS143ITEM19. EXHIBITS143 CONVENTIONS THAT APPLY TO THIS ANNUAL REPORT ON FORM20-F Unless otherwise indicated, references in this annual report on Form20-F to: ●“ADRs” refers to the American depositary receipts, which, if issued, evidence our ADSs;●“ADSs” refers to our American depositary shares, each of which represents 30 Class A ordinary shares;●“China” or “PRC” refers to the People’s Republic of China, and only in the context of describing the industry matters, the PRC laws, rules, regulations,regulatory authorities, and any PRC entities or citizens under such rules, laws and regulations and other legal or tax matters in this annual report, excludesTaiwan and the special administrative regions of Hong Kong and Macau;●“Concord Healthcare” refers to Concord Healthcare Group Co., Ltd. (formerly known as Meizhong Jiahe Medical Science & Technology DevelopmentGroup Co., Ltd.);●“Concord Medical,” “we,” “us,” “our company,” “our group” or “our” refers to Concord Medical Services Holdings Limited, its predecessor entities and itsconsolidated subsidiaries;●“ordinary shares” refers to our ordinary shares, par value US$0.0001 per share, which can be divided into Class A ordinary shares and Class B ordinaryshares;●“PRC subsidiaries” refers to our subsidiaries incorporated in the People’s Republic of China, including Concord Healthcare, Shenzhen Aohua MedicalTechnology Development Co., Ltd. (“Aohua Technology”), Shanghai Taifeng Medical Technology Co., Ltd., Shanghai Meizhong Jiahe Yunying OutpatientCenter Co., Ltd. (“Shanghai General Practice Clinic”), Medstar (Shanghai) Enterprise Management Co., Ltd. (“Shanghai Medstar”), Tianjin ConcordMedical Technology Co., Ltd., Jiaxue (Shanghai) Medical Technology Services Co., Ltd., Beijing Century Friendship Science & Technology DevelopmentCo., Ltd. (“Beijing Century Friendship”), Beijing Proton Medical Center Co., Ltd (“Beijing Proton Medical Center”), Shanghai Concord Cancer CenterCo., Ltd. (“Shanghai Hospital”), Shanghai Meizhong Jiahe Imaging Diagnostics Center Co., Ltd. (“Shanghai Imaging Center”), Shanghai Meizhong JiaheCancer Center Co., Ltd. (“Shanghai Outpatient Department”), Shanghai Taizhi Medical Technology Services Co., Ltd., Beijing Yundu Internet TechnologyCo., Ltd. (“Beijing Yundu”), Guangzhou Concord Cancer Center Co., Ltd. (“Guangzhou Hospital”), Ningbo Jiahe Hospital Management Co., Ltd.,Yinchuan Taizhi Technology Services Co., Ltd. (“Yinchuan Meizhong Jiahe Internet Hospital”), Guangzhou Concord Medical Sci-Tech Innovation CenterLtd., Beijing Healthingkon Technology Co., Ltd. (“Healthingkon”), Beijing Concord Medical Technology Co., Ltd., Wuxi Concord Medical DevelopmentCo., Ltd. (“Wuxi Concord Medical Development”), Wuxi Meizhong Jiahe Cancer Center Co., Ltd. (“Wuxi Hospital”), Shanghai Hexinkang TechnicalService Co., Ltd. and Guangzhou Concord Pharmacy Co., Ltd.●“RMB” or “Renminbi” refers to the legal currency of China;●“US$,” “U.S. dollars,” “$” or “dollars” refers to the legal currency of the United States of America;●“£” refers t